NANasar Aslam

Nasar Aslam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nasar Aslam has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dedicated Endoscopy for Barrett's Oesophagus With Higher Dysplasia Yield May Reduce Seattle Protocol Biopsies: Results From UK Multicentre Study

    by Champika Gamakaranage, James Britton, Elizabeth Ratcliffe, Neeraj Prasad, Richard Keld, Mark Murgatroyd, Shanmugasundaram Balakrishnan, Nazar Aslam, Vinay Sehgal, Jenni Marsh, et al.

    Background: Dedicated service for Barrett's oesophagus (BO) surveillance may be more effective than conventional service, according to some single centre studies. Objective: To determine whether the surveillance of BO through a dedicated service can improve key performance indicators (KPIs), and dysplasia detection rate (DDR) compared with conventional service in a multi centre study. Methods: A retrospective cohort study was conducted across 6 NHS‐hospitals, capturing BO surveillance data over 8 years. Factors associated with DDR were assessed by logistic regression. Results: There were 1037 dedicated and 976 conventional surveillance procedures ( N = 2013), male: female ratio = 2.2:1; mean age = 64.4 (SD ± 12.2) years; mean maximum length of BO = 4.1 cm (range: 0–18 cm). All the KPIs and DDR were significantly higher in the dedicated service (DDR = 6.9%) than in the conventional service (DDR = 2.8%), p < 0.001. The use of narrow band imaging (NBI) and acetic acid chromoendoscopy (AAC) and sedation were high, and the complication rate was significantly lower in the dedicated service. The lesion recognition was significantly associated with DDR (OR = 6.9). Surprisingly, Seattle biopsy protocol adherence showed no correlation with DDR (OR = 0.47). Conclusion: The dedicated service provides higher quality endoscopy, and a higher yield of early neoplasia. It uses more sedation, advanced imaging, and detects more lesions than conventional services. Thus, the dedicated surveillance could potentially replace time and cost consuming Seattle biopsies with targeted biopsies of visible lesions. In future, this may become easier with the use of artificial intelligence for lesion detection (CADe).


  • Advances in therapeutic upper gastrointestinal endoscopy (Part 1): what’s new in this field?

    by Anjan Dhar, Vikramjit Mitra, David Leonard, Nasar Aslam, Benjamin Charles Norton, Samer Al-Dury, Noor Mohammed, Vinay Sehgal, Rehan Haidry

    For the last two decades, upper gastrointestinal endoscopy has been a diagnostic procedure carried out for investigations of malabsorption or gastrointestinal bleeding. However, in the last 10 years, rapid advances have been made in therapeutic upper gastrointestinal endoscopy for a range of gastrointestinal conditions, for the treatment of benign and early neoplastic lesions, management of advanced cancer and expanding indications of metabolic endoscopy and gastro-oesophageal reflux disease. The repertoire of therapeutic procedures in the upper gastrointestinal tract now include resection and ablation of early neoplastic lesions associated with Barrett’s oesophagus, endoscopic submucosal dissection for early squamous neoplasia of the oesophagus and early gastric cancer, resection of duodenal lesions, resection of subepithelial lesions, management of benign and malignant stenosis, third space endoscopic procedures for achalasia (per oral endoscopic myotomy, POEM) and for gastroparesis (G-POEM), treatment of Zenker’s diverticulum (Z-POEM), endoscopic sutured gastroplasty and duodenal ablation procedures for treatment of obesity and diabetes, and endoscopic vacuum therapy for management of leaks, defects and fistulas. In the first of a two-part series on therapeutic upper gastrointestinal endoscopy, we aim to describe some of these innovations with indications, a brief description of the procedure and the evidence base for their use in gastrointestinal endoscopy.

  • Open Access

    Combined oesophageal and airway stenting for malignant oesophageal strictures: a retrospective cohort study and development of a novel algorithm

    by Julian Gertner, Monica L Mullin, Rosalind Shea, Nasar Aslam, Matthew Banks, Omer F Ahmad, Rami Sweis, David Graham, Neal Navani, Ricky Thakrar, et al.

    Objective Malignant oesophageal strictures can cause airway compromise and fistula formation. Combined oesophageal and airway stenting is a potential treatment, yet no guidelines exist. This study aims to describe the outcomes of same-session oesophageal and airway endoscopic stenting for malignant strictures and propose an algorithm for intervention. Method A retrospective cohort study on patients undergoing same-session gastrointestinal (GI) and respiratory endoscopy at University College London Hospital between 2019 and 2023. Data collected included malignancy type, degree of luminal narrowing (%), completed interventions, complications and mortality. The primary objective was to describe interventions performed during same-session procedures, with a focus on developing a decision-based algorithm. Results 26 patients were identified with a mean age of 63 years. Primary cancer type was oesophageal (81%) or lung (19%). The most common referral indication was dysphagia (42%), although radiological signs of airway compromise were frequently seen on imaging (65%). Stent insertion included oesophageal only (35%), airway only (19%) and dual (27%). After oesophageal stenting, repeat bronchoscopy showed increased airway stenosis in four patients (25%). There was only one intraoperative complication, an oesophageal perforation. New tracheo-oesophageal fistula was the most common post-intervention complication (15%). Median time from malignancy diagnosis to death was 7.9 weeks. Conclusion Malignant oesophageal strictures with airway involvement are a challenging condition to treat. Given the complexity of cases, joint upper GI and respiratory multidisciplinary discussion is suggested to plan any intervention including same-session endoscopy. To our knowledge, we present the first algorithm for endoscopic stenting in patients with malignant oesophageal stricture and airway involvement. Decision-making should be framed by patient-centred goals, as this group demonstrated poor prognosis.


  • Open Access

    Endoscopic Suturing for Defect Closure in the Upper Gastrointestinal Tract: A Retrospective Cohort Study

    by Apostolis Papaefthymiou, Nasar Aslam, Benjamin Norton, Andrea Telese, Charles Murray, Alberto Murino, Gavin Johnson, Roberto Simons-Linares, Rehan Haidry

    Background: The increasing availability of gastrointestinal (GI) interventions has raised the need to treat luminal defects. Endoscopic suturing (ES) is a minimally invasive technique that is used for a wide range of indications. This retrospective cohort study aimed to evaluate the performance of ES in treating upper GI defects. Materials and Methods: Data from a tertiary centre were collected for patients undergoing ES to treat upper GI defects. The primary outcome was long-term outcomes, defined as the successful sutures deployment. Secondary outcomes included technical success, immediate clinical success (confirmation of closure at the time of the procedure), recurrence, and complications. Descriptive statistics and x2 test were used to calculate the rates of the outcomes and assess any link between independent variables and results. Results: Forty-two procedures were performed on 25 patients between 2018 and 2023. The mean age was 55 (±16.2) years, and 56% were female. The long-term clinical success rate was 69.6% (16/23), the technical success rate was 88.1% (37/42), and the immediate clinical success rate was 91.9% (34/37), with only two (4.8%) adverse events. The overall recurrence rate was 61.8% (21/34). Technical success was higher in the esophagus (92.3%), and stomach (100%) (p = 0.002), and immediate clinical success was more likely in patients with leaks (88.9%) or fistula (95.2%) compared to perforation (50%; p = 0.005). Conclusions: ES demonstrated high rates of technical and immediate clinical success for defect closure in the upper GI tract, with low rates of complications. The benefit is most prominently seen among patients with leaks and fistulas in the stomach and esophagus.


  • Open Access

    Metabolic and Bariatric Endoscopy: A Mini-Review

    by Benjamin Charles Norton, Andrea Telese, Apostolis Papaefthymiou, Nasar Aslam, Janine Makaronidis, Charles Murray, Rehan Haidry

    We are currently in a worldwide obesity pandemic, which is one of the most significant health problems of the 21st century. As the prevalence of obesity continues to rise, new and innovate treatments are becoming available. Metabolic and bariatric endoscopic procedures are exciting new areas of gastroenterology that have been developed as a direct response to the obesity crisis. These novel interventions offer a potentially reversible, less invasive, safer, and more cost-effective method of tackling obesity compared to traditional bariatric surgery. Minimally invasive endoscopic treatments are not entirely novel, but as technology has rapidly improved, many of the procedures have been proven to be extremely effective for weight loss and metabolic health, based on high-quality clinical trial data. This mini-review examines the existing evidence for the most prominent metabolic and bariatric procedures, followed by a discussion on the future trajectory of this emerging subspecialty.


  • Open Access

    Minimally invasive endoscopic therapies for gastro-oesophageal reflux disease

    by Nasar Aslam, Andrea Telese, Vinay Sehgal, Rami Sweis, Laurence B Lovat, Rehan Haidry

    The prevalence of the gastro-oesophageal reflux disease (GORD) in the western world is increasing. Uncontrolled GORD can lead to harmful long-term sequela such as oesophagitis, stricture formation, Barrett’s oesophagus and oesophageal adenocarcinoma. Moreover, GORD has been shown to negatively impact quality of life. The current treatment paradigm for GORD consists of lifestyle modification, pharmacological control of gastric acid secretion or antireflux surgery. In recent years, several minimally invasive antireflux endoscopic therapies (ARET) have been developed which may play a role in bridging the unmet therapeutic gap between the medical and surgical treatment options. To ensure optimal patient outcomes following ARET, considered patient selection is crucial, which requires a mechanistic understanding of individual ARET options. Here, we will discuss the differences between ARETs along with an overview of the current evidence base. We also outline future research priorities that will help refine the future role of ARET.


  • Open Access

    A review of the therapeutic management of ulcerative colitis

    by Nasar Aslam, Sheng Wei Lo, Rafid Sikafi, Tom Barnes, Jonathan Segal, Philip J Smith, Jimmy K Limdi

    Ulcerative colitis (UC) is a chronic relapsing and remitting gastrointestinal disorder of uncertain aetiology. The last two decades have seen an expansion in the therapeutic arsenal used to treat UC. This has resulted in improved clinical remission and response rates. Nonetheless, staples in our current medical management originate from trials conducted in the early 20th century. In this review article, we aim to outline the key milestones in the history of the medical management of UC in addition to highlighting promising therapeutic developments for the future.


  • P143 Performance of a convolutional neural network for Barrett’s oesophagus related dysplasia detection following quality labelling

    by Nasar Aslam, Mohamed Hussein, Rawen Kader, Anton Mejias, Patrick Brandao, Juana Gonzalez-Bueno Puyal, Peter Mountney, Danail Stoyanov, Laurence Lovat, Rehan Haidry

    Introduction Invasive oesophageal adenocarcinoma arising in Barrett’s oesophagus (BE) can occur in up to 25% of patients one year after index endoscopic examination. Computer assisted diagnosis may reduce the incidence of overlooked early neoplasia in BE patients. Our group has previously trained a convolutional neural network (CNN) that achieves dysplasia detection rates comparable to expert endoscopists. The aim of this study was to evaluate the effect that image quality has on the performance of our CNN. Methods We previously trained a CNN with Resnet101 architecture to classify videos frames according to the presence or absence of dysplasia. All available video frames demonstrating dysplasia from high-definition white light and i-scan Pentax (Hoya, Japan) imaging modes were used as part of the training for the CNN. Histology from mucosal resection specimens or biopsies served as the ground truth for the presence of dysplasia. Low- or high-quality markers were assigned to each frame with dysplasia present. Quality labelling was assigned by a single reviewer. Factors that influenced quality labelling included overall visibility of the dysplastic lesion, motion blur, light speculation, or artefact. Results A total of 23513 frames of dysplastic BE were assigned quality labels across 17 cases. 17915 frames were labelled as high quality with 5598 being of low quality. Evaluating the CNN performance solely on high quality frames yielded an overall sensitivity of 84.61%. When testing against both high- and low-quality frames the CNN achieved an overall sensitivity of 82.26% (table 1). Performance of the CNN following quality labelling Conclusions Evaluating the performance of our CNN on a combination of high- and low-quality dysplastic frames yields comparable overall sensitivity to testing solely on high quality dysplastic frames. Real time endoscopy captures a mix of high- and low-quality frames which is influenced by factors such as artefact, patient tolerance and scope stability. The comparable performance of our CNN will be valuable for future real time application.

  • P140 Transoral incisionless fundoplication using the EsophyX Z+ device: a UK first experience

    by Nasar Aslam, Vinay Sehgal, Mohamed Hussein, Rami Sweis, Laurence Lovat, Rehan Haidry

    Introduction Gastroesophageal reflux disease (GORD) is becoming increasingly prevalent in the western world. Lifestyle modification and medical therapy remain first line interventions, although anti-reflux surgery remains a choice in select individuals. Advances in endoscopic anti-reflux procedures have shown promise as an additional treatment option. Here we present the first UK experience of treating patients with confirmed GORD with Transoral incisionless fundoplication (TIF) 2.0 using the EsophyX Z+ device. Methods Data was collected retrospectively from 46 patients who underwent TIF 2.0 between November 2019 and February 2022 at a specialist centre. GERD-Health-Related Quality of Life (GERD-HRQL) questionnaires were used to evaluate treatment response. Results TIF 2.0 was performed in 46 patients, (29 male and 17 Female). The mean patient age at the time of procedure was 50 ± 17.3 years. Baseline physiology metrics following 96-hour BRAVOTM reflux testing were available for 38 patients. The mean DeMeester score at baseline was 31.62 ± 15.4. The median acid exposure time (% time pH Conclusions This represents UK’s first experience of TIF 2.0. Our growing cohort of patients undergoing TIF corroborates recent published data showing that it is a safe and effective procedure. Further, in patients in whom we have follow up data, there is a clear improvement in quality-of-life metrics, thus highlighting its potential as a viable endoscopic treatment option for patients with troublesome GORD. Limitations to this study are the retrospective observational design, heterogenous follow up data with the possibility of self-selection bias in follow up questionnaires. This may impact the generalisability of results. Further collection of outcomes using standardised study protocols with a larger patient cohort from different centres will help build upon the UK experience.

  • Open Access

    Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going

    by Eleanor Liu, Nasar Aslam, Gaurav Nigam, Jimmy K Limdi

    Inflammatory bowel diseases, comprising ulcerative colitis (UC) and Crohn’s disease, are chronic, immune-mediated and progressive inflammatory disorders affecting the gastrointestinal tract. Tofacitinib is the first oral small-molecule Janus kinase (JAK) inhibitor licensed and approved by the National Institute for Health and Care Excellence (NICE) for use in moderately-to-severely active UC after intolerance, inadequate response, or loss of response to conventional treatment or biologic therapy. The pivotal OCTAVE studies demonstrated the efficacy and safety of tofacitinib for the induction and maintenance of remission in UC. A growing body of evidence from real-world data supports the positive clinical and endoscopic benefits observed with tofacitinib treatment in the OCTAVE trials. This narrative review summarizes the current literature regarding the mechanism of action of tofacitinib, data from registrational trials, emerging real-world evidence, and an overview of the most recent safety evidence. We explore evolving treatment paradigms, including the use of tofacitinib in the COVID-19 era, pregnancy and extraintestinal manifestations, as well as the emerging concept of combining tofacitinib with biological therapy. We will also present a brief overview of the next generation of JAK inhibitors in the pipeline.